Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!


A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults - MB006-017

Updated: 10 October, 2019   |   ClinicalTrials.gov

Print Friendly Summary

Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1


  • Gender(s)

  • 18-60

    Age Range

  • 1


  • Recruiting

Treatment Options

Study Arms
Experimental: BMS-963272 or Placebo every 12 hours (Q12H)
Drug: BMS-963272 Drug: Placebo
Experimental: BMS-963272 or Placebo every 8 hours (Q8H)
Drug: BMS-963272 Drug: Placebo
Experimental: BMS-963272 or Placebo once daily (QD)
Drug: BMS-963272 Drug: Placebo

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Participants must be in good general health, in the opinion of the investigator, with no clinically significant deviation from normal in medical history, physical examination findings, ECGs, or laboratory results. - Participants must have a BMI of 30 kg/m2 to 40 kg/m2 inclusive - Women (not of childbearing potential) and men aged 18 to 60 years, inclusive Exclusion Criteria: - Previous participation in the current study - Inability or unwillingness to comply with protocol-defined restrictions or requirements regarding lifestyle, diet, concomitant medications, or other aspects of the study - Inability to tolerate the oLTT meal or to comply with oLTT testing conditions - Inability to tolerate oral medication - Inability to tolerate venipuncture and/or inadequate venous access - Women who are breastfeeding - Medical Conditions - History of lactose intolerance - Any significant (in the opinion of the investigator) acute or chronic illness - Type 1 or 2 diabetes - Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population - Previous/Concomitant Therapy - Previous exposure to BMS-963272 Other protocol-defined inclusion/exclusion criteria could apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Email Us

Have questions?
Email Us